The Experts below are selected from a list of 67308 Experts worldwide ranked by ideXlab platform
Siegfried Kasper - One of the best experts on this subject based on the ideXlab platform.
-
Severe Depression and antidepressants focus on a pooled analysis of placebo controlled studies on agomelatine
International Clinical Psychopharmacology, 2007Co-Authors: Stuart A. Montgomery, Siegfried KasperAbstract:The efficacy of agomelatine in Severe Depression has been examined in three positive placebo-controlled studies and in a pooled analysis of the data from the three studies in patients treated with 25-50 mg agomelatine (n=357) and placebo (n=360). Agomelatine was significantly more effective than placebo in a subgroup of patients with Severe Depression with a severity of 25 or more on the Hamilton Depression Rating Scale 17-item scale in each individual study (P<0.05) and in the pooled analysis (P<0.001). Analysis of the pooled data demonstrated that there was an increase in the magnitude of the agomelatine-placebo difference with increasing severity on the baseline Hamilton Depression Rating Scale. When the population was divided into subgroups using increasing cut-off Hamilton Depression Rating Scale values a significant difference between agomelatine and placebo was observed in each subgroup despite the decreasing numbers of patients with higher severity with a difference of 2.06 rising to 4.45 points on the Hamilton Depression Rating Scale. In conclusion, agomelatine is effective in treating Severe Depression.
-
Severe Depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
International clinical psychopharmacology, 2007Co-Authors: Stuart A. Montgomery, Siegfried KasperAbstract:The efficacy of agomelatine in Severe Depression has been examined in three positive placebo-controlled studies and in a pooled analysis of the data from the three studies in patients treated with 25-50 mg agomelatine (n=357) and placebo (n=360). Agomelatine was significantly more effective than placebo in a subgroup of patients with Severe Depression with a severity of 25 or more on the Hamilton Depression Rating Scale 17-item scale in each individual study (P
-
Cost-Effectiveness of Escitalopram versus Citalopram in the Treatment of Severe Depression
The Annals of pharmacotherapy, 2004Co-Authors: Michiel E. H. Hemels, Siegfried Kasper, Evelyn Walter, Thomas R. EinarsonAbstract:BACKGROUND:Severe Depression is associated with an extensive economic burden on both the patient and society.OBJECTIVE:To estimate the cost-effectiveness in Austria of escitalopram compared with citalopram in the management of Severe Depression (Montgomery—Asberg Depression Rating Scale score ≥30).METHODS:A decision model incorporated treatment paths and associated direct resource use (psychiatric hospitalization, medications, general practitioner and psychiatrist visits, treatment discontinuation, suicide attempts) associated with managing Severe Depression and the indirect cost of work absenteeism over a 6-month period. Main outcomes were clinical success (remission at 6 mo) and cost (2002 Euros equals ∼1.25 US) of treatment. The analysis was performed from the Austrian societal and Social Healthcare Insurance System (SHIS) perspectives. Clinical input data were derived from a meta-analysis of 8-week randomized clinical trials. Costs were derived from standard Austrian price lists or from the literature...
-
Is Severe Depression a different illness? The pharmacological evidence
European Neuropsychopharmacology, 1993Co-Authors: Siegfried KasperAbstract:Abstract Relatively little is known about the comparative efficacy of selective serotonin reuptake inhibitors and tricyclic antidepressants in patients suffering from Severe Depression. Furthermore, clinicians question if this new group of antidepressants are effective in Severe Depression at all. However, the results of recent studies indicate that fluvoxamine, fluoxetine and paroxetine can be successfully used in Severely depressed patients.
Armin Szegedi - One of the best experts on this subject based on the ideXlab platform.
-
differentiating moderate and Severe Depression using the montgomery asberg Depression rating scale madrs
Journal of Affective Disorders, 2003Co-Authors: Matthias J Muller, Hubertus Himmerich, Barbara Kienzle, Armin SzegediAbstract:Background: MADRS cut-off scores for moderate and Severe Depression were estimated in relation to the Hamilton Depression Rating Scale (HAMD17) and the Clinical Global Impressions Scale (CGI). Method: HAMD17, MADRS, and CGI ratings from patients with major Depression (DSM-IV) were analyzed (N=85). Receiver operating characteristics (ROC) curves were applied. Results: Mean age was 51.4±14.5 years, 69% were female. Mean MADRS scores were 23.4±13.2, HAMD17, MADRS, and CGI scores were highly correlated (r>0.85; P<0.0001). Best separation between moderate and Severe Depression according to CGI criteria was achieved with a MADRS score of 31 (sensitivity 93.5%, specificity 83.3%). Limitations: Studies to validate severity gradations including DSM-IV or ICD-10 diagnostic severity categories are recommended. Conclusions: Empirically based MADRS cut-off scores to separate moderate from Severe Depression on the basis of HAMD17 and CGI severity ratings in patients with major Depression were yielded.
-
Differentiating moderate and Severe Depression using the Montgomery-Asberg Depression rating scale (MADRS).
Journal of affective disorders, 2003Co-Authors: Matthias J Muller, Hubertus Himmerich, Barbara Kienzle, Armin SzegediAbstract:Background: MADRS cut-off scores for moderate and Severe Depression were estimated in relation to the Hamilton Depression Rating Scale (HAMD17) and the Clinical Global Impressions Scale (CGI). Method: HAMD17, MADRS, and CGI ratings from patients with major Depression (DSM-IV) were analyzed (N=85). Receiver operating characteristics (ROC) curves were applied. Results: Mean age was 51.4±14.5 years, 69% were female. Mean MADRS scores were 23.4±13.2, HAMD17, MADRS, and CGI scores were highly correlated (r>0.85; P
-
Moderate and Severe Depression: Gradations for the Montgomery–Åsberg Depression Rating Scale
Journal of affective disorders, 2000Co-Authors: Matthias J Muller, Armin Szegedi, Hermann Wetzel, Otto BenkertAbstract:Background: Despite its importance, no distinction between moderate and Severe Depression using the Montgomery–Asberg Depression Rating Scale (MADRS) based on a direct comparison with the Hamilton Depression Rating Scale (HAMD-17) is available. Methods: HAMD-17 and MADRS ratings from N=40 at least moderately depressed inpatients with major Depression (DSM-III-R) were analyzed. Linear and non-parametric correlations were computed and a MADRS cut-off score for Severe Depression using an HAMD-17 score of at least 28 points as reference was estimated. Results: HAMD-17 and MADRS mean scores were 24.6±4.3 and 32.6±5.0 points, respectively. Linear correlation of both scores was r=0.70 (P
Matthias J Muller - One of the best experts on this subject based on the ideXlab platform.
-
differentiating moderate and Severe Depression using the montgomery asberg Depression rating scale madrs
Journal of Affective Disorders, 2003Co-Authors: Matthias J Muller, Hubertus Himmerich, Barbara Kienzle, Armin SzegediAbstract:Background: MADRS cut-off scores for moderate and Severe Depression were estimated in relation to the Hamilton Depression Rating Scale (HAMD17) and the Clinical Global Impressions Scale (CGI). Method: HAMD17, MADRS, and CGI ratings from patients with major Depression (DSM-IV) were analyzed (N=85). Receiver operating characteristics (ROC) curves were applied. Results: Mean age was 51.4±14.5 years, 69% were female. Mean MADRS scores were 23.4±13.2, HAMD17, MADRS, and CGI scores were highly correlated (r>0.85; P<0.0001). Best separation between moderate and Severe Depression according to CGI criteria was achieved with a MADRS score of 31 (sensitivity 93.5%, specificity 83.3%). Limitations: Studies to validate severity gradations including DSM-IV or ICD-10 diagnostic severity categories are recommended. Conclusions: Empirically based MADRS cut-off scores to separate moderate from Severe Depression on the basis of HAMD17 and CGI severity ratings in patients with major Depression were yielded.
-
Differentiating moderate and Severe Depression using the Montgomery-Asberg Depression rating scale (MADRS).
Journal of affective disorders, 2003Co-Authors: Matthias J Muller, Hubertus Himmerich, Barbara Kienzle, Armin SzegediAbstract:Background: MADRS cut-off scores for moderate and Severe Depression were estimated in relation to the Hamilton Depression Rating Scale (HAMD17) and the Clinical Global Impressions Scale (CGI). Method: HAMD17, MADRS, and CGI ratings from patients with major Depression (DSM-IV) were analyzed (N=85). Receiver operating characteristics (ROC) curves were applied. Results: Mean age was 51.4±14.5 years, 69% were female. Mean MADRS scores were 23.4±13.2, HAMD17, MADRS, and CGI scores were highly correlated (r>0.85; P
-
Moderate and Severe Depression: Gradations for the Montgomery–Åsberg Depression Rating Scale
Journal of affective disorders, 2000Co-Authors: Matthias J Muller, Armin Szegedi, Hermann Wetzel, Otto BenkertAbstract:Background: Despite its importance, no distinction between moderate and Severe Depression using the Montgomery–Asberg Depression Rating Scale (MADRS) based on a direct comparison with the Hamilton Depression Rating Scale (HAMD-17) is available. Methods: HAMD-17 and MADRS ratings from N=40 at least moderately depressed inpatients with major Depression (DSM-III-R) were analyzed. Linear and non-parametric correlations were computed and a MADRS cut-off score for Severe Depression using an HAMD-17 score of at least 28 points as reference was estimated. Results: HAMD-17 and MADRS mean scores were 24.6±4.3 and 32.6±5.0 points, respectively. Linear correlation of both scores was r=0.70 (P
Stuart A. Montgomery - One of the best experts on this subject based on the ideXlab platform.
-
Severe Depression and antidepressants focus on a pooled analysis of placebo controlled studies on agomelatine
International Clinical Psychopharmacology, 2007Co-Authors: Stuart A. Montgomery, Siegfried KasperAbstract:The efficacy of agomelatine in Severe Depression has been examined in three positive placebo-controlled studies and in a pooled analysis of the data from the three studies in patients treated with 25-50 mg agomelatine (n=357) and placebo (n=360). Agomelatine was significantly more effective than placebo in a subgroup of patients with Severe Depression with a severity of 25 or more on the Hamilton Depression Rating Scale 17-item scale in each individual study (P<0.05) and in the pooled analysis (P<0.001). Analysis of the pooled data demonstrated that there was an increase in the magnitude of the agomelatine-placebo difference with increasing severity on the baseline Hamilton Depression Rating Scale. When the population was divided into subgroups using increasing cut-off Hamilton Depression Rating Scale values a significant difference between agomelatine and placebo was observed in each subgroup despite the decreasing numbers of patients with higher severity with a difference of 2.06 rising to 4.45 points on the Hamilton Depression Rating Scale. In conclusion, agomelatine is effective in treating Severe Depression.
-
Severe Depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
International clinical psychopharmacology, 2007Co-Authors: Stuart A. Montgomery, Siegfried KasperAbstract:The efficacy of agomelatine in Severe Depression has been examined in three positive placebo-controlled studies and in a pooled analysis of the data from the three studies in patients treated with 25-50 mg agomelatine (n=357) and placebo (n=360). Agomelatine was significantly more effective than placebo in a subgroup of patients with Severe Depression with a severity of 25 or more on the Hamilton Depression Rating Scale 17-item scale in each individual study (P
-
The antidepressant efficacy of reboxetine in patients with Severe Depression.
Journal of clinical psychopharmacology, 2003Co-Authors: Stuart A. Montgomery, James M Ferguson, Gerri E SchwartzAbstract:We examined the effectiveness of reboxetine, a norepinephrine reuptake inhibitor (NRI), compared with placebo for the treatment of patients with Severe major Depression (defined as a score on the 17-item Hamilton Rating Scale for Depression [HAM-D] >/=25). Data were obtained from four prospective, double-blind, randomized, placebo-controlled clinical trials of the efficacy of reboxetine (8 to 10 mg/d) over 4 to 8 weeks in patients with major Depression. In three of the trials, reboxetine produced a significantly greater reduction than placebo in mean HAM-D scores from baseline to the last clinical assessment (p 50% between baseline and the last follow-up observation) treated with reboxetine than placebo in three trials. The overall mean responder rate with reboxetine was 63% (range: 56-74%) compared with 36% (range: 20-52%) with placebo. These results demonstrate that reboxetine is significantly more effective than placebo in a subgroup of patients with Severe Depression.
Louise Brådvik - One of the best experts on this subject based on the ideXlab platform.
-
Aspects of Additional Psychiatric Disorders in Severe Depression/Melancholia: A Comparison between Suicides and Controls and General Pattern
MDPI AG, 2018Co-Authors: Ulrika Heu, Mats Bogren, August G. Wang, Louise BrådvikAbstract:Objective: Additional and comorbid diagnoses are common among suicide victims with major depressive disorder (MDD) and have been shown to increase the suicide risk. The aim of the present study was first, to investigate whether patients with Severe Depression/melancholia who had died by suicide showed more additional psychiatric disorders than a matched control group. Second, general rates of comorbid and additional diagnoses in the total group of patients were estimated and compared with literature on MDD. Method: A blind record evaluation was performed on 100 suicide victims with Severe Depression/melancholia (MDD with melancholic and/or psychotic features: MDD-M/P) and matched controls admitted to the Department of Psychiatry, Lund, Sweden between 1956 and 1969 and monitored to 2010. Diagnoses in addition to Severe Depression were noted. Results: Less than half of both the suicides and controls had just one psychiatric disorder (47% in the suicide and 46% in the control group). The average number of diagnoses was 1.80 and 1.82, respectively. Additional diagnoses were not related to an increased suicide risk. Anxiety was the most common diagnosis. Occurrence of suspected schizophrenia/schizotypal or additional obsessive-compulsive symptoms were more common than expected, but alcohol use disorders did not appear very frequent. Conclusions: The known increased risk of suicide in MDD with comorbid/additional diagnoses does not seem to apply to persons with MDD-M/P (major depressive disorder-Depression/Melancholia). Some diagnoses, such as schizophrenia/schizotypal disorders, were more frequent than expected, which is discussed, and a genetic overlap with MDD-M/P is proposed
-
Mental disorders in suicide and undetermined death in the Lundby Study. The contribution of Severe Depression and alcohol dependence.
Archives of suicide research : official journal of the International Academy for Suicide Research, 2010Co-Authors: Louise Brådvik, Mats Bogren, Cecilia Mattisson, Per NettelbladtAbstract:To evaluate the role of Severe Depression, i.e., Depression with melancholic and/or psychotic features and alcohol dependence in suicide and undetermined death. The Lundby Study is a prospective, longitudinal study of a population consisting of 3563 subjects. In a long-term follow up 1947-2006 there were 66 suicide cases, including 19 undetermined deaths. Depression and alcoholism were as expected the major contributors to suicide (44% and 23% respectively). Severe Depression with psychotic and/or melancholic features was diagnosed in 66% of all Depressions and in 29% of all suicide cases, as compared to 15% for major Depression only. Alcohol dependence was related to undetermined death. Major depressive disorder with melancholic and/or psychotic features appears to be an important contributor to accomplished suicide in the Depression group, and alcohol dependence appears to be related to undetermined death.
-
Suicide in Severe Depression related to treatment, depressive characteristics and rate of antidepressant overdose
European archives of psychiatry and clinical neuroscience, 2004Co-Authors: Louise Brådvik, Mats BerglundAbstract:The objective of the present study was to assess the association between depressive characteristics and completed suicide despite adequate antidepressant therapy in Severe Depression and to investigate the frequency of lethal antidepressant overdoses. A record evaluation of 98 suicide victims with a primary Severe Depression had been performed. These had been admitted to the Department of Psychiatry, Lund University Hospital between 1956 and 1969 and followed up to 1998. Psychomotor retardation was related to completed suicide after ECT. The estimated frequency of lethal intoxication with antidepressants was low: 3% of the suicides.
-
Suicide after suicide attempt in Severe Depression: a long-term follow-up.
Suicide & life-threatening behavior, 2003Co-Authors: Louise BrådvikAbstract:The temporal relation between completed suicide and first-ever suicide attempt was investigated in 58 future suicides with a primary Severe Depression/melancholia. The median survival after a first attempted suicide was 6.7 years. Male patients with initial ratings of psychomotor retardation lived significantly longer after their initial attempt than those who were not retarded. They also had more depressive episodes compared to other male suicides and retarded controls. Thus a slow suicidal process in the men with a Severe Depression and psychomotor retardation is proposed. Severity, repetition, and method of suicide attempt did not decrease the survival time.
-
The occurrence of suicide in Severe Depression related to the months of the year and the days of the week.
European archives of psychiatry and clinical neuroscience, 2002Co-Authors: Louise BrådvikAbstract:The purpose of the present study was to investigate the distribution of suicide during the months of the year and the days of the week in Severe Depression. A total of 1206 in-patients rated at discharge from the Department of Psychiatry, Lund, Sweden, on a multiaxial diagnostic schedule received the diagnosis Severe Depression/melancholia between 1956 to 1969. When followed up to 1998, a total of 114 depressed patients had taken their own life. Out of these, 98 patients appeared to have a primary Depression. The monthly distribution of suicides showed a significant peak in October/November for men (41 % of all male suicides). No correlation with the onset of Depression could be detected. Furthermore, there was a preponderance of suicide on Sundays for both sexes (31 % of all suicides).
